Alzheimer drugs: How donanemab compares to lecanemab
网页How does donanemab compare to lecanemab? Eli Lilly's press release suggests that donanemab slows cognitive decline by 35%. Lecanemab trial results showed it slowed cognitive decline by 27%.
Preparing for disease-modifying therapies in Alzheimer's disease
网页2023年7月15日 · The drugs closest to widespread clinical implementation are lecanemab and donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from the brain and can slow cognitive and functional decline.
Alzheimer’s drug with modest benefits wins backing of FDA advisers
网页2024年6月10日 · Research 1, 2 shows that donanemab slows symptoms roughly as well as rival drug lecanemab, which also attacks amyloid. Lecanemab is made by the biopharmaceutical companies Eisai in Tokyo and...
Trial of Donanemab in Early Symptomatic Alzheimer Disease
网页Numerous amyloid-targeting therapy trials failed to show appreciable slowing of clinical disease progression 4-7; however, aducanumab, lecanemab, and donanemab recently showed promising amyloid plaque clearance, potentially benefitting patients. 8-10
Are lecanemab and donanemab disease-modifying therapies?
网页2024年8月3日 · Encouraging results from two large 18-month, double-blind, placebo-controlled studies of the anti-amyloid beta (Aβ) monoclonal antibodies (mAb) lecanemab 1 and donanemab 2 in early Alzheimer's disease (AD) have motivated claims that they are disease-modifying.
Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease ...
网页2023年6月13日 · In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer’s disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; alternatively, their limited efficiency could be intrinsic.
Alzheimer’s drug donanemab: what promising trial means for
网页2023年5月4日 · Like lecanemab, donanemab targets amyloid protein, which is thought to cause dementia by accumulating in the brain and damaging neurons. The trial results provide strong evidence that amyloid...
Donanemab in Early Alzheimer’s Disease | NEJM
网页2021年3月13日 · Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer’s disease. Methods. We conducted a phase 2 trial of donanemab in...
Lecanemab and Donanemab as Therapies for Alzheimer's Disease: …
网页2024年7月1日 · Lecanemab and Donanemab as Therapies for Alzheimer's Disease: An Illustrated Perspective on the Data. eNeuro. 2024 Jul 1;11 (7):ENEURO.0319-23.2024. doi: 10.1523/ENEURO.0319-23.2024. Print 2024 Jul. Authors. Alberto J Espay 1 , Kasper P Kepp 2 , Karl Herrup 3. Affiliations.
Lecanemab in Early Alzheimer’s Disease | NEJM
网页2022年11月29日 · Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with...
跳至内容